Lipocalin-2 negatively modulates the epithelial-to-mesenchymal transition in hepatocellular carcinoma through the epidermal growth factor (TGF-beta1)/Lcn2/Twist1 pathway
0301 basic medicine
Carcinoma, Hepatocellular
Epithelial-Mesenchymal Transition
Liver Neoplasms
Down-Regulation
Mice, Nude
Nuclear Proteins
In Vitro Techniques
Lipocalins
Disease Models, Animal
Mice
03 medical and health sciences
Phenotype
Lipocalin-2
Cell Line, Tumor
Disease Progression
Animals
Heterografts
Humans
Neoplasm Invasiveness
Acute-Phase Proteins
Cell Proliferation
DOI:
10.1002/hep.26467
Publication Date:
2013-05-20T21:46:53Z
AUTHORS (7)
ABSTRACT
Lipocalin-2 (Lcn2) is preferentially expressed in hepatocellular carcinoma (HCC). However, the functional role of Lcn2 HCC progression still poorly understood, particularly with respect to its involvement invasion and metastasis. The purpose this study was investigate whether associated epithelial-mesenchymal transition (EMT) elucidate underlying signaling pathway(s). well-differentiated versus liver cirrhosis tissues, expression positively correlated stage HCC. characteristics EMT were reversed by adenoviral transduction into SH-J1 cells, including down-regulation N-cadherin, vimentin, alpha-smooth muscle actin, fibronectin, concomitant up-regulation CK8, CK18, desmoplakin I/II. Knockdown short hairpin RNA (shRNA) HKK-2 cells expressing high levels EMT. Epidermal growth factor (EGF) or transforming beta1 (TGF-β1) treatment resulted Lcn2, accompanied an increase Twist1 cells. Stable reduced expression, inhibited cell proliferation vitro, suppressed tumor metastasis a mouse model. Furthermore, EGF TGF-β1 barely changed marker ectopically Lcn2. Ectopic induced even indicating that functions downstream factors upstream Twist1.Together, our findings indicate can negatively modulate through (or TGF-β1)/Lcn2/Twist1 pathway. Thus, may be candidate suppressor potential therapeutic target
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (44)
CITATIONS (69)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....